Hemophilia A treatment might change forever thanks to a breakthrough in gene therapy protein design. AAVnerGene Inc. has secured U.S. Patent No. 12583907, titled ‘Modified plasma clotting factor VIII and method of use thereof’. This innovation targets the root cause of bleeding disorders by enhancing the stability of essential blood-clotting proteins.
Enhanced Stability for Better Care
Traditional treatments for Hemophilia A involve frequent and costly infusions. These injections replace missing clotting factors but often lose effectiveness quickly. The new patent describes a modified protein with specific amino acid changes. These tweaks make the protein more stable and active within the body. This breakthrough ensures the factor stays in the bloodstream longer to prevent dangerous bleeding events.
A New Era of Gene Therapy
The modified factor VIII works seamlessly with viral vectors for long-term delivery. This approach could reduce the need for constant medical visits and painful injections. Patients may experience fewer spontaneous bleeds and improved quality of life. By optimizing the protein structure, the company makes gene therapy more efficient and affordable for everyone. This technology simplifies the manufacturing process for complex biological drugs.
Transforming Hemophilia Treatment
The new technology represents a major leap in biotechnology. It offers a clear path toward more durable and accessible treatments. The medical community now has a powerful tool to fight genetic bleeding conditions. This research highlights the impact of precision engineering in modern medicine. It marks a significant milestone for patients seeking long-term relief from chronic symptoms.
Learn More:
Are you developing new or improved products, or thinking of applying for a patent? Did you know your research work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? To find out more, please check out our free online eligibility test.
Feel free to book a quick teleconference with one of R&D Tax specialists if you would like to learn more about R&D Tax Credit opportunities.
Who We Are:
Swanson Reed is one of the largest Specialist R&D Tax Credit advisory firm in the United States. With offices nationwide, we are one of the only firms globally to exclusively provide R&D Tax Credit consulting services to our clients. We have been exclusively providing R&D Tax Credit claim preparation and audit compliance solutions for over 30 years.
Swanson Reed’s Maryland office provides R&D tax credit consulting and advisory services to Baltimore, Frederick, Rockville, Gaithersburg, Bowie, Hagerstown, Annapolis, College Park, Salisbury, and Laurel.
Swanson Reed hosts daily free webinars and provides free IRS CE and CPE credits for CPAs. For more information please click here or contact your usual Swanson Reed representative.“”
Hemophilia A treatment might change forever thanks to a breakthrough in gene therapy protein design. AAVnerGene Inc. has secured U.S. Patent No. 12583907, titled ‘Modified plasma clotting factor VIII and method of use thereof’. This innovation targets the root cause of bleeding disorders by enhancing the stability of essential blood-clotting proteins.
Enhanced Stability for Better Care
Traditional treatments for Hemophilia A involve frequent and costly infusions. These injections replace missing clotting factors but often lose effectiveness quickly. The new patent describes a modified protein with specific amino acid changes. These tweaks make the protein more stable and active within the body. This breakthrough ensures the factor stays in the bloodstream longer to prevent dangerous bleeding events.
A New Era of Gene Therapy
The modified factor VIII works seamlessly with viral vectors for long-term delivery. This approach could reduce the need for constant medical visits and painful injections. Patients may experience fewer spontaneous bleeds and improved quality of life. By optimizing the protein structure, the company makes gene therapy more efficient and affordable for everyone. This technology simplifies the manufacturing process for complex biological drugs.
Transforming Hemophilia Treatment
The new technology represents a major leap in biotechnology. It offers a clear path toward more durable and accessible treatments. The medical community now has a powerful tool to fight genetic bleeding conditions. This research highlights the impact of precision engineering in modern medicine. It marks a significant milestone for patients seeking long-term relief from chronic symptoms.
Learn More:
Are you developing new or improved products, or thinking of applying for a patent? Did you know your research work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? To find out more, please check out our free online eligibility test.
Feel free to book a quick teleconference with one of R&D Tax specialists if you would like to learn more about R&D Tax Credit opportunities.
Who We Are:
Swanson Reed is one of the largest Specialist R&D Tax Credit advisory firm in the United States. With offices nationwide, we are one of the only firms globally to exclusively provide R&D Tax Credit consulting services to our clients. We have been exclusively providing R&D Tax Credit claim preparation and audit compliance solutions for over 30 years.
Swanson Reed’s Maryland office provides R&D tax credit consulting and advisory services to Baltimore, Frederick, Rockville, Gaithersburg, Bowie, Hagerstown, Annapolis, College Park, Salisbury, and Laurel.
Swanson Reed hosts daily free webinars and provides free IRS CE and CPE credits for CPAs. For more information please click here or contact your usual Swanson Reed representative.
Are you eligible?
Why choose us?
Pass an Audit?
What is the R&D Tax Credit?
The Research & Experimentation Tax Credit (or R&D Tax Credit), is a general business tax credit under Internal Revenue Code section 41 for companies that incur research and development (R&D) costs in the United States. The credits are a tax incentive for performing qualified research in the United States, resulting in a credit to a tax return. For the first three years of R&D claims, 6% of the total qualified research expenses (QRE) form the gross credit. In the 4th year of claims and beyond, a base amount is calculated, and an adjusted expense line is multiplied times 14%. Click here to learn more.
Never miss a deadline again
Stay up to date on IRS processes
Discover R&D in your industry
R&D Tax Credit Preparation Services
Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.
If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.
R&D Tax Credit Audit Advisory Services
creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.
Our Fees
Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/
Choose your state
